Denali Advisors’s PDL BioPharma, Inc. PDLI Stock Holding History

Denali Advisors’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-330	Closed	-$1K	–	289
2018 Q4	$1K	Hold	330	–	–	﹤0.01%	248
2018 Q3	$1K	Hold	330	–	–	﹤0.01%	250
2018 Q2	$1K	Hold	330	–	–	﹤0.01%	272
2018 Q1	$1K	Hold	330	–	–	﹤0.01%	263
2017 Q4	$1K	Hold	330	–	–	﹤0.01%	266
2017 Q3	$1K	Hold	330	–	–	﹤0.01%	261
2017 Q2	$1K	Hold	330	–	–	﹤0.01%	261
2017 Q1	$1K	Hold	330	–	–	﹤0.01%	267
2016 Q4	$1K	Hold	330	–	–	﹤0.01%	276
2016 Q3	$1K	Hold	330	–	–	﹤0.01%	280
2016 Q2	$1K	Hold	330	–	–	﹤0.01%	279
2016 Q1	$1K	Hold	330	–	–	﹤0.01%	281
2015 Q4	$1K	Hold	330	–	–	﹤0.01%	277
2015 Q3	$2K	Hold	330	–	–	﹤0.01%	254
2015 Q2	$2K	Sell	330 -449,600	-100%	-$3.01M	﹤0.01%	263
2015 Q1	$3.17M	Sell	449,930 -347,900	-44%	-$2.52M	0.73%	54
2014 Q4	$6.15M	Sell	797,830 -35,200	-4%	-$279K	1.74%	17
2014 Q3	$6.22M	Buy	833,030 +567,300	+213%	+$5.27M	1.79%	15
2014 Q2	$2.57M	Buy	+265,730	New	+$2.37M	0.7%	56

Other funds holding PDLI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Denali Advisors's PDLI Position: Q1 2019 in Review

Denali Advisors sold out of PDL BioPharma, Inc. (PDLI) in Q1 2019, closing a stake of 330 shares — an estimated $1K sold.

Denali Advisors first reported a position in PDLI in Q2 2014 and held it in 19 quarters. The position peaked at $6.22M in Q3 2014. 157 funds tracked by Wall St. Rank hold PDLI as of Q1 2019.

Denali Advisors reported no remaining PDL BioPharma, Inc. position as of Q1 2019 after selling out during the quarter.
Denali Advisors sold 330 PDL BioPharma, Inc. shares in Q1 2019, an estimated $1K.
Denali Advisors first reported a position in PDL BioPharma, Inc. in Q2 2014 and held it in 19 quarters.
Denali Advisors's PDL BioPharma, Inc. position peaked at $6.22M in Q3 2014.
157 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q1 2019.

Based on Denali Advisors's 13F filing for Q1 2019, filed 9 Apr 2019.